Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00153_DB00930_nanopub.RA7SmnZUv3obaK8tG_Pp6pA9CuKPLq6IC16QRjduUV7Rs#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00153_DB00930 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00153_DB00930 label "DDI between Ergocalciferol and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. [drugbank_resource:DB00153_DB00930]" assertion.
- drugbank_resource:DB00153_DB00930 identifier "drugbank_resource:DB00153_DB00930" assertion.
- drugbank_resource:DB00153_DB00930 title "DDI between Ergocalciferol and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs." assertion.
- drugbank:DB00930 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00153_DB00930 assertion.
- drugbank:DB00153 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00153_DB00930 assertion.